Topline data were announced from two phase 3 studies evaluating tegoprazan in patients with gastroesophageal reflux disease ... including Los Angeles grade C or D erosive esophagitis (secondary ...

The FDA has approved vonoprazan as a therapy for erosive gastroesophageal reflux disease ... for patients with moderate to severe disease (Los Angeles grade C/D) at week 2, indicating its rapid ...

Tegoprazan met all primary and secondary endpoints in non-erosive reflux disease (NERD ... cohort of patients with severe disease (LA Grades C & D). In the NERD trial, tegoprazan demonstrated ...

lansoprazole in 1,250 patients, including 463 with LA Grade C/D esophagitis ... reinforcing its potential as a differentiated treatment option in GERD. The safety and tolerability of tegoprazan were ...

Approximately one quarter of the 11,945 GERD patients in these 5 trials had severe EE (defined as LA grades C or D), regardless of their baseline heartburn severity. Conclusion: The severity of ...

GERD is a common condition worldwide ... Consensus was achieved through careful evaluation using the GRADE concept 14 to define the quality of the supporting evidence based on study design ...

The efficacy of continuous antibiotic prophylaxis in preventing urinary tract infection (UTI) in infants with grade III, IV, or V vesicoureteral reflux is controversial. In this investigator ...